Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given
together with pembrolizumab in treating patients with stage IV triple negative breast cancer
that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and
ruxolitinib phosphate together may work better in treating patients with stage IV triple
negative breast cancer.